Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma

Keyphrases

• Pembrolizumab 100%
• Sebaceous Carcinoma 100%
• Microsatellite Stable 100%
• Near-complete Response 100%
• Liver 40%
• Natural Killer Cells 40%
• Response to Therapy 40%
• Older Men 20%
• Lung 20%
• Head-and-neck 20%
• Lymph Node 20%
• CD8+ T Cells 20%
• Sebaceous Gland 20%
• High Dose 20%
• Memory T Cells 20%
• Replacement Therapy 20%
• Metastasis 20%
• Brain Metastases 20%
• Initial Treatment 20%
• Therapeutic Response 20%
• Effector Memory 20%
• Clinical Response 20%
• Peripheral Blood 20%
• Anti-PD-1 20%
• Prospective Clinical Trial 20%
• Adrenal Insufficiency 20%
• Radiological Response 20%
• Bowel 20%
• Abdominal Lymph Nodes 20%
• PD-L1 Expression 20%
• Eyelid 20%
• CD57 20%
• Systemic Corticosteroids 20%
• Response Evaluation Criteria in Solid Tumors (RECIST) 20%
• Central Memory 20%
• CD14+CD16+ 20%
• Memory Phenotype 20%
• Checkpoint Blockade 20%
• Cutaneous Adnexal Tumors 20%
• Postoperative Radiosurgery 20%

Medicine and Dentistry

• Sebaceous Carcinoma 100%
• Pembrolizumab 100%
• Lymph Node 40%
• Natural Killer Cell 40%
• Immunotherapy 40%
• Clinical Trial 20%
• Neck 20%
• Memory T Cell 20%
• Programmed Death-Ligand 1 20%
• Drug Megadose 20%
• Cytotoxic T-Cell 20%
• Metastatic Carcinoma 20%
• Brain Metastasis 20%
• Substitution Therapy 20%
• Treatment Response 20%
• Adrenal Insufficiency 20%
• Skin Tumor 20%
• Sebaceous Gland 20%
• Case Presentation 20%
• Radiosurgery 20%
• Corticosteroid 20%
• Eyelid 20%